Stacey Titus • October 4, 2023
Welcome The Christ Hospital Health Network HCM Program – Cincinnati, OH

The Christ Hospital HCM Clinic is a multidisciplinary cardiovascular program. The HCM Clinic provides patient-specific care and collaborates with subspecialties within the institution to address the complexity often associated with hypertrophic cardiomyopathy.  The Christ Hospital provides a team of subspecialized cardiologists, electrophysiologists, CT, and Vascular Surgeons with various advanced diagnostic services and treatments.  In addition, the HCM Clinic offers dedicated support staff, including a devoted physician’s assistant, registered nurse, HCM program coordinator, medical assistant, and HCM scheduler.  The mission of The Christ Hospital’s HCM program is that they are committed to providing the highest quality of care to hypertrophic cardiomyopathy patients in our community by forming personalized strategies to empower each patient along their clinical pathway. Their vision is to “Create a seamless and accessible pathway for hypertrophic cardiomyopathy patients.  The Christ Hospital HCM program is excited to be able to offer a nationally respected team of physicians and have at our patient’s disposal today’s most advanced therapies for the treatment and management of hypertrophic cardiomyopathy.”

HCM Program Director Dr. Wojciech Mazur and HCM Program Co-Director Dr. Ankit Bhatia say, “Our HCM clinical team recognizes the uniqueness of each individual patient diagnosed with HCM. We truly pride ourselves in the time we spend getting to know more about their challenges and victories. Our working relationship with the HCMA has made us more aware of the needs of HCM patients, and we have modeled our program to address current gaps in HCM management. The Christ Hospital Hypertrophic Cardiomyopathy Clinic is the second center of excellence in the state of Ohio, which will now open up more opportunities for our community. We are excited to offer our patients the most up-to-date medical management as well as enrollment into ground-breaking research trials.” 

Team Members:

  • Wojciech Mazur, MD HCM Clinic Director
  • Ankit Bhatia, MD HCM Clinic Co-Director
  • J Michael Smith, MD Surgery
  • Dean Kereiakes, MD Interventional Cardiology
  • Puvi Seshiah, MD Interventional Cardiology
  • Edward Schloss, MD Electrophysiology
  • Daniel Pelchovitz, MD Electrophysiology
  • Gregory Egnaczyk, MD Advanced Heart Failure
  • Burns Blaxall, PHd Genetics
  • Courtney Hannum, LGC Genetics
  • Abigail Patterson, PA Physician Assistant
  • Cassady Palmer, Cardiac Research Sonographer

Please visit for more information:

The Christ Hospital Health Network HCM Program –  Cincinnati, OH please visit:  https://4hcm.org/christhosp/

Watch the live announcement and introduction of The Christ Hospital Team:   https://www.youtube.com/watch?v=eq-cN8qssHM&list=PLmfkg8wc_HI_d1l4l2W1ZhptO-bMjW_rb&index=1


For more information on all HCMA Recognized Centers of Excellence, please visit  https://4hcm.org/center-of-excellence/.

HCMA Blog

By Erica Friedman June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized
By Erica Friedman June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam
By Erica Friedman June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts